Trevi Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Trevi Therapeutics, Inc. (TRVI) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $9.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-17
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $9.00K.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $9.00K.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.29M, a 32125.00% increase from fiscal 2022.
- Trevi Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $9.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $9.00K 10-Q · filed 2025-11-13 | $9.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $9.00K 10-Q · filed 2025-08-07 | $9.00K derived: sum of 3 quarters · filed 2026-03-17 | $9.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $9.00K 10-Q · filed 2025-05-08 | $9.00K derived: sum of 2 quarters · filed 2026-03-17 | $9.00K derived: sum of 3 quarters · filed 2026-03-17 | $9.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $0.00 derived: sum of 3 quarters · filed 2025-03-18 | $1.29M 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $1.29M 10-Q · filed 2024-11-06 | $1.29M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.29M 10-Q · filed 2024-08-08 | $1.29M derived: sum of 3 quarters · filed 2024-08-08 | $1.29M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.29M 10-Q · filed 2024-05-07 | $1.29M derived: sum of 2 quarters · filed 2024-05-07 | $1.29M derived: sum of 3 quarters · filed 2024-05-07 | $1.30M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $4.00K derived: sum of 2 quarters · filed 2024-03-20 | $8.00K derived: sum of 3 quarters · filed 2024-03-20 | $4.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $4.00K 10-Q · filed 2023-11-09 | $8.00K derived: sum of 2 quarters · filed 2023-11-09 | $4.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $4.00K 10-Q · filed 2023-08-10 | $4.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |